January 2024
1. MAHASE E
   Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
   BMJ. 2024;384:q59.
   

   >> Share

   
   August 2023
2. LANG K
   How do we best use Paxlovid and other covid antivirals?
   BMJ. 2023;382:p1666.
   

   >> Share

   
   July 2022
3. TANNE JH
   Covid-19: FDA authorises pharmacists to prescribe Paxlovid.
   BMJ. 2022;378:o1695.
   

   >> Share

   
   June 2022
4. PHIZACKERLEY D
   Three more points about Paxlovid for covid-19.
   BMJ. 2022;377:o1397.
   

   >> Share

   
   May 2022
5. MONEER O, Daly G, Skydel JJ, Nyhan K, et al
   Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
   BMJ. 2022;377:e069400.
   

   >> Share

   
   April 2022
6. EXTANCE A
   Covid-19: What is the evidence for the antiviral Paxlovid?
   BMJ. 2022;377:o1037.
   

   >> Share

   
   May 2021
7. PRATS-URIBE A, Sena AG, Lai LYH, Ahmed WU, et al
   Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
   BMJ. 2021;373:n1038.
   

   >> Share

   
   December 2020
8. 
   Update to living WHO guideline on drugs for covid-19.
   BMJ. 2020;371:m4779.
   

   >> Share

   
   July 2020
9. SIEMIENIUK RA, Bartoszko JJ, Ge L, Zeraatkar D, et al
   Drug treatments for covid-19: living systematic review and network meta-analysis.
   BMJ. 2020;370:m2980.
   

   >> Share

   
   
10. GRIFFIN S
    Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.
    BMJ. 2020;370:m2650.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share